Pay in 4 interest-free payments of $5.90 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
& Issekutz, A
Moderate medication interactions have been identified, and safety information is well characterized
Your body also needs energy to function and be productive when youre awake
Hypertension 75 , 13341357 (2020)
Add-on to 1-3 oral anti-hyperglycemic agents (metformin, sulfonylurea, or SGLT-2 inhibitor) SURPASS-4 (NCT03730662) was a 104-week open-label trial (52-week primary endpoint) that randomized 2002 adult patients with type 2 diabetes mellitus with increased cardiovascular risk to subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg once weekly, or insulin glargine 100 units/mL once daily (1:1:1:3 ratio) on a background of metformin (95%) and/or sulfonylureas (54%) and/or SGLT2 inhibitors (25%)
The price remains flat across all dose levelsyour dose may need to go up, but your price won't
US$ 29.89
US$ 28.15
US$ 20.86
US$ 25.32
US$ 23.85
